SandboxAQ and iOncologi Partner To Accelerate Brain Cancer Treatment With AI-Driven Drug Discovery for Glioblastoma
SandboxAQ and UF startup iOncologi have announced a strategic collaboration to co-develop, validate, and commercialize a novel high-fidelity mRNA vaccine targeting glioblastoma—the most common and aggressive malignant brain tumor in adults.
Myosin Therapeutics Receives FDA Clearance To Initiate First-in-Human Trial of MT-125 in Glioblastoma
UF startup Myosin Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for MT-125.
UF-Developed mRNA Vaccine Triggers Fierce Immune Response To Fight Malignant Brain Tumor
In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine developed at the University of Florida quickly reprogrammed the immune system to attack glioblastoma, the most aggressive and lethal brain tumor.